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Forty-two antigenic domains were identified across the hepatitis A virus (HAV) polyprotein by using a set of 237 overlapping
20-mer synthetic peptides spanning the entire HAV polyprotein and a panel of serum samples from acutely HAV-infected
patients. The term “antigenic domain” is used in this study to define a protein region spanned with consecutive overlapping
immunoreactive peptides. Nineteen antigenic domains were found within the structural proteins, and 22 were found within
the nonstructural proteins, with 1 domain spanning the junction of VP1 and P2A proteins. Five of these domains were
considered immunodominant, as judged by both the breadth and the strength of their immunoreactivity. One domain is
located within the VP2 protein at position 57–90 aa. A second domain, located at position 767–842 aa, contains the C-terminal
part of the VP1 protein and the entire P2A protein. A third domain, located at position 1403–1456 aa, comprises the C-terminal
part of the P2C protein and the N-terminal half of the P3A protein. The fourth domain, located at position 1500–1519 aa,
includes almost the entire P3B, and the last domain, located at position 1719–1764 aa, contains the C-terminal region of the
P3C protein and the N-terminal region of the P3D protein. It is interesting to note that four of the five most immunoreactive
domains are derived from small HAV proteins and/or encompass protein cleavage sites separating different HAV proteins.
The HAV-specific immunoreactivity of each antigenically reactive peptide was confirmed by using seven HAV seroconversion
panels. Collectively, these data demonstrate that HAV structural and nonstructural proteins contain antigenic epitopes that
can be efficiently modeled with short synthetic peptides.
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Hepatitis A virus (HAV), the causative agent of hepati-
is A, is a unique member of the family Picornaviridae
Gust et al., 1983; Minor, 1991). The HAV genome is a
ositive single-stranded RNA, 7.5 kb in length. Similar to
ll Picornaviridae, the HAV genome contains one large
pen reading frame encoding a polyprotein, which is
ventually cleaved into smaller structural and nonstruc-
ural proteins (Hollinger and Ticerhurst, 1996).
The antigenic composition of the intact virions has
een thoroughly studied. Multiple antigenic epitopes
ave been detected on the surface of virions and 14S
entamer subunits by using monoclonal antibodies. It
as shown that almost all epitopes are located within
ne immunodominant neutralization site (Lemon and
obertson, 1993; Ping and Lemon, 1992; Stapleton and
emon, 1987); however, other studies using chimeric
icornaviruses have suggested the existence of a sec-
ndary neutralization site near the N-terminus of VP1
1 To whom correspondence and reprint requests should be ad-
ressed at Hepatitis Branch, MS A-33, Division of Viral and Rickettsial
iseases, National Center for Infectious Diseases, Centers for Disease
ontrol and Prevention, 1600 Clifton Road, Atlanta, GA 30333. Fax: (404)e39-1563. E-mail: yek0@cdc.gov.
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260Lemon et al., 1992). This finding confirmed a previous
bservation that peptide derived from the N-terminal
egions of VP1 induced HAV neutralizing antibodies
Emini et al., 1985). Most murine HAV monoclonal anti-
odies compete with one another, and these antibodies
an substantially block polyclonal human antibodies
rom binding HAV in competition immunoassays (Hughes
t al., 1984; Stapleton and Lemon, 1987). These obser-
ations suggest that there are only a limited number of
ntigenic epitopes closely placed on the surface of viri-
ns. Polyclonal or monoclonal antibodies obtained
gainst native HAV demonstrated only marginal reactivity
ith denatured capsid proteins (Lemon, 1992). Similarly,
ntibodies raised to purified capsid proteins VP1, VP2,
nd VP3 did not efficiently neutralize HAV (Hughes and
tanton, 1985). These observations led to the suggestion
hat the antigenic epitopes of HAV are mainly conforma-
ional discontinuous structures that assemble by higher
rder interactions between capsid proteins (Lemon and
ing, 1988; Lemon, 1992).
Several approaches have been taken to map the HAV
eutralizing epitopes. By cross-linking the Fab fragment
f one HAV neutralizing monoclonal antibody to the VP1
rotein in intact virions, it was shown that this protein
lays an essential role in forming the HAV neutralizing
pitope (Hughes et al., 1984). Another approach was to
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261ANTIGENIC EPITOPES OF HEPATITIS A VIRUSdentify mutations within the HAV capsid proteins that
esult in resistance to neutralization with monoclonal
ntibodies. Neutralization escape mutations for the HAV
train HM175 were identified at Asp70, Gln74 of the VP3
rotein, Ser102, Val171, Ala176, and Lys221 of the VP1 protein
Ping et al., 1988; Ping and Lemon, 1992), and for strain
AS15 at Pro65, Asp70, and Ser71 of VP3 and at Asn104,
ys105, and Gln232 of the VP1 protein (Nainan et al., 1992).
Synthetic peptides have been extensively used to
dentify diagnostically relevant antigenic epitopes within
he structural proteins (Bosch et al., 1998; Chikin et al.,
991; Kulik et al., 1994, 1995); however, all attempts to
ind these epitopes have been unsuccessful (Bosch et
l., 1998; Chikin et al., 1991; Kulik et al., 1994, 1995). This
bservation was considered as additional evidence of
he strict conformational nature of the HAV capsid anti-
enic sites. In order to overcome this conformational
imitation on modeling HAV epitopes with synthetic pep-
ides a new approach based on selection of desired
mmunoreactive peptides from random sequence pep-
ide libraries (Houghten et al., 1991; Scott and Smith,
990) was employed to discover a mimotope that reacted
ith monoclonal and polyclonal anti-HAV antibodies
Mattioli et al., 1995). A synthetic peptide containing this
imotope very efficiently detected IgM anti-HAV activity
n serum specimens of acutely infected patients, al-
hough it failed to efficiently detect IgG antibodies (Mat-
ioli et al., 1995).
The HAV nonstructural proteins are also antigenically
eactive. An assay based on immune precipitation of
roteins translated in vitro has been developed to detect
ntibodies against the HAV nonstructural proteins (Jia et
l., 1992). This assay was used to discriminate between
ntibodies after natural infection and vaccination (Rob-
rtson et al., 1992, 1993). Antibodies against P2 proteins
ere found in all sera from acutely infected patients,
hereas chimpanzees vaccinated with inactivated or
ell-adapted HAV had no detectable antibodies against
2 products (Robertson et al., 1993). In another study, an
nzyme immunoassay (EIA) was developed to detect
ntibodies to the nonstructural P3C protein. Antibodies
o this protein were detected in the serum of primates
xperimentally infected with virulent HAV and in the se-
um of acutely infected patients, but antibodies to P3C
rotein were not detected in the serum from primates
ollowing immunization with inactivated HAV (Stewart et
l., 1997). These findings demonstrate the utility of HAV
onstructural proteins in differentiating inactivated vac-
ine-induced immunity from natural infection. However,
o further studies on the antigenic composition of these
roteins were conducted.
HAV infection is diagnosed by the detection of IgM or
gG antibodies to the capsid proteins (Bradley et al.,
977). Because of apparently poor antigenic reactivity,
AV recombinant proteins and synthetic peptides have
ot been successfully employed in an EIA for the detec- pion of anti-HAV activity. Currently, the only available
ource of immunoreactive proteins for assay develop-
ent is inactivated HAV derived from cell culture, which
s currently used by all commercial companies that man-
facture anti-HAV tests. In addition to the inconvenience
nd cost associated with the production, purification,
nd standardization of cell culture-derived HAV antigen,
urrent commercially available assays are unable to dis-
riminate between natural infections and vaccine in-
uced immunity, as emphasized in several publications
Jia et al., 1992; Robertson et al., 1992, 1993; Steward et
l., 1997), since these tests utilize intact HAV and there-
ore will detect antibodies in either case.
The present study provides, for the first time, a com-
rehensive analysis of the antigenic composition of the
ntire HAV polyprotein by using a large number of syn-
hetic peptides. The results demonstrate the existence of
everal broadly and strongly antigenically reactive re-
ions, many of which have significant diagnostic poten-
ial within both structural and nonstructural proteins.
RESULTS AND DISCUSSION
eptide design
The sequence of the polyprotein of the HAV from strain
M175 (Cohen et al., 1987) was used to design all syn-
hetic peptides in this study. A total of 237 overlapping
0-mer peptides were synthesized. Almost the entire
equence of the HAV HM175 polyprotein was spanned
ith these peptides with only a few exceptions: four
mall hydrophobic regions at positions 106–109, 1011–
029, 1471–1476, and 1546–1547 aa were not spanned
ith peptides. In addition, in three cases peptides were
erived from adjacent nonoverlapping hydrophobic re-
ions in such a way that positions 980–981, 1087–1088,
nd 1107–1108 aa were represented only at the termini of
eptides. These seven regions are shown in Fig. 1C as
arger than average gaps between small vertical bars.
ome regions where antigenic activity has been shown
reviously (Emini et al., 1985; Kulik et al., 1994, 1995;
ainan et al., 1992; Ping et al., 1988; Ping and Lemon,
992) or could be predicted with high probability (Jame-
on and Wolf, 1988) based on protein chain flexibility
Karplus and Schultz, 1985), hydrophylicity (Kyte and
oolittle, 1982), and/or secondary structure (Chou, 1990)
ere spanned with a higher peptide density. These re-
ions can be identified in Fig. 1C as clusters of small
ertical bars. For example, two clusters of peptides
ithin the N-terminal part of the VP3 protein (Fig. 1C)
ere generated around an antigenic epitope that had
een previously reported (Kulik et al., 1995) and around
esidues Asp315 and Gln319 (shown by two asterisks in Fig.
C) that have been found to be essential to the HAV
ajor conformational neutralizing epitope (Ping et al.,
988; Ping and Lemon, 1992). Within the VP1 protein,
eptide clusters were synthesized around an antigenic
262 KHUDYAKOV ET AL.
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263ANTIGENIC EPITOPES OF HEPATITIS A VIRUSpitope that had been previously found to elicit neutral-
zing antibody (Emini et al., 1985; Lemon et al., 1992);
round amino acid residues Ser593, Val662, Ala667, and
ys712 (indicated by asterisks in Fig. 1C), which were
hown to be important for the functional activity of the
ajor HAV neutralizing antigenic epitope (Ping and
emon, 1992); and around the region at position 714–752
a that was shown to be exposed on the surface of HAV
articles (Robertson et al., 1989). Surface exposure is
enerally considered to be an important indicator of
otential antigenic reactivity (Emini et al., 1985).
On average, every amino acid of the HAV HM175
olyprotein was represented 2.1 times in these synthe-
ized peptides. Peptides were overlapped on average by
0 aa. In peptide clusters, peptides were often over-
apped by 14–18 aa. Among 237 peptides, 110 were
erived from structural proteins and 127 were derived
rom nonstructural proteins. Thus, taking into consider-
tion the difference in the size of the HAV structural
egion (791 aa) and the nonstructural region (1436 aa),
he density of peptides derived from structural proteins is
pproximately 1.6 times greater than that from nonstruc-
ural proteins.
mmunoreactivity of peptides derived from structural
roteins
The antigenic reactivity of the HAV structural proteins
as been extensively investigated using synthetic pep-
ides (Bosch et al., 1998; Chikin et al., 1991; Kulik et al.,
994, 1995), and strong antigenic regions modeled with
hort synthetic peptides or with recombinant proteins
ere not ascertained. In this study, however, a number of
trong antigenic epitopes were discovered. These con-
radicting results may be explained by: (1) the use of
cute-phase serum specimens in the present study,
hereas all previous studies employed convalescent-
hase serum specimens or polyclonal or monoclonal
ntibodies obtained against HAV particles and (2) a thor-
ugh scan of each protein by using significantly overlap-
ing peptides.
VP4–VP2 proteins.Among 21 peptides derived from the
P4–VP2 proteins, 10 were found immunoreactive with
cute anti-HAV serum specimens, as indicated by the
ertical bars in Fig. 1. These immunoreactive peptides
FIG. 1. Antigenic reactivity of synthetic peptides. (A) HAV polyprotei
ertical bars show the location of the center of each synthesized pept
eptide; shaded area shows the average percentage immunoreactivity
ercentage immunoreactivity for all peptides; (E) average P/N ratio calc
here P represents the OD493 of anti-HAV-positive specimens and N re
/N value for peptides derived from each protein and the dotted line s
aterials and Methods); dark shaded area shows the average A index
alue that is two times greater than the average A index for the entire po
lack bars, alpha-helix; shaded bars, beta-structure; small black bars, b
982): hydrophilic regions are shown above the line.ere used to identify 6 antigenic domains, as indicated
y alternating consecutive rows of the same shade in
able 1. In this study, an antigenic domain is defined as
protein region spanned with immunoreactive consec-
tive overlapping synthetic peptides or a single peptide
eparated from other antigenic regions by nonimmuno-
eactive peptides. For example, four domains of the VP4–
P2 protein, at positions 15–34, 35–54, 194–213, and
14–233 aa, were identified with only one peptide each.
wo domains at positions 57–90 and 110–156 aa were
panned with three peptides each (Table 1). Three pep-
ides (1210, 1211, and 1216) from the two largest domains
ithin the VP4–VP2 region demonstrated broad immuno-
eactivity with acute anti-HAV-positive serum specimens.
hese peptides immunoreacted with more than 30.0% of
ested serum specimens with a range from 32.6 to 56.1%.
ll three peptides contain antigenic epitopes that have
ot been previously reported. Overlapping peptides, 1215
nd 1216, demonstrated approximately a two times
igher background immunoreactivity with anti-HAV-neg-
tive serum specimens (data not shown). Also, peptide
216 demonstrated nonspecific immunoreactivity with 4
f 46 anti-HAV negative specimens (Table 1). Thus, the
egion at position 110–143 aa, as modeled with two
onsecutive overlapping synthetic peptides, exhibited
AV nonspecific reactivity under the experimental con-
itions that were uniformly applied to all peptides (see
aterials and Methods).
Several peptides comprising regions 65–85 aa (Chikin
t al., 1991), 92–122 aa (Kulik et al., 1994, 1995), 103–122
a (Kulik et al., 1994), and 119–130 aa (Bosch et al., 1998)
rom the HAV VP2 protein and region 1–23 aa from the
AV VP4 protein have been synthesized and tested with
nti-HAV-positive serum specimens previously. Among
hese peptides, only one, containing sequence 65–85 aa,
as found to be not immunoreactive (Chikin et al., 1991).
owever, this peptide significantly overlaps with the
trongly immunoreactive peptide 1211, which contains
his sequence (Table 1). The overlapping peptides 92–
22 (Kulik et al., 1994, 1995)and 103–122 aa (Kulik et al.,
994) were found immunoreactive with convalescent-
hase serum specimens and monoclonal antibodies ob-
ained against the whole virus. These two peptides share
equences with peptide 1214, which is not immunoreac-
ntigenic domains; 1–5, most immunoreactive antigenic domains; (C)
) percentage of serum specimens that are immunoreactive with each
ptides derived from each protein and dotted line shows the average
for all serum specimens immunoreactive with each synthetic peptide,
ts the OD493 of negative specimens; shaded area shows the average
he average P/N for all peptides; (F) the A index for each peptide (see
tides derived from each protein, and the light shaded area shows the
n shown by dotted line; (G) predicted secondary structure (Chou, 1990):
s; horizontal line, random coil; (H) hydropathic plot (Kyte and Doolittle,n; (B) a
ide; (D
for pe
ulated
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264 KHUDYAKOV ET AL.ive and includes the sequence 87–106 aa, and peptide
215, which is immunoreactive and comprises the se-
uence 110–129 aa. It is conceivable that the overlapping
egion between these three immunoreactive peptides at
osition 110–122 aa may represent at least an essential
art of a common antigenic epitope. The other immuno-
eactive peptide, described by Bosch et al. (1998) and
omprising region 119–130 aa, essentially overlaps im-
unoreactive peptide 1215 containing the sequence
10–129 aa (Table 1). Thus, the common antigenic
pitope modeled with these peptides may be located
ithin the region at position 119–129 aa. It is interesting
T
Antigenic Reactivity of Synthetic Peptid
Note. Alternating boldface and italic type represent individual antig
1 The number of positive serum samples divided by the total numb
2 Mean P/N value; number in parentheses indicates the range of P
3 Normal human sera.
4 Background reactivity with anti-HAV-negative sera is two times go note that the last region contains residue Tyr123, which uas found exposed on the surface of HAV particles
Robertson et al., 1989). Peptide comprising the entire
AV VP4 protein (1–23 aa) has been synthesized and
hown not to be immunoreactive with anti-HAV-positive
onvalescent-phase serum specimens (Chikin et al.,
991). Two peptides that overlap this sequence were
sed in this study. One peptide comprising the sequence
–19 aa was not immunoreactive, while the other pep-
ide, 1206, was immunoreactive (Table 1). Since the pep-
ide containing the region 1–23 aa was tested by using
onvalescent-phase serum specimens, which are, in
eneral, less immunoreactive than the acute specimens
ived from the HAV Structural Proteins
omains.
ested sera and percentage of immunoreactive sera.
ues.
than that for other peptides.ABLE 1
es Der
enic d
er of t
/N valsed in the present study, it is impossible to determine
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265ANTIGENIC EPITOPES OF HEPATITIS A VIRUShether the VP4 region at position 15–23 aa, as repre-
ented within peptide 1206 (Table 1), contains an anti-
enic epitope or the antigenic reactivity is attributed
ntirely to the N-terminal part (24–34 aa) of the VP2
rotein included within this peptide.
VP3 protein. Among 37 peptides spanning the entire
AV VP3 protein, 11 peptides were found to be immuno-
eactive (Fig. 1). An analysis of overlapping immunore-
ctive peptides allowed the identification of five anti-
enic domains within this protein (Table 1). Two C-termi-
al domains of the VP3 protein were identified with one
eptide each, while the N-terminal domain was identified
ith two overlapping peptides. Two central domains
ere identified with three and four immunoreactive syn-
hetic peptides (Table 1), respectively. Four peptides
1236, 1249, 1250, and 1261) that belong to three different
ntigenic domains were found to be broadly immunore-
ctive. These peptides demonstrated immunoreactivity
ith more than 30.0% of anti-HAV-positive serum speci-
ens. Therefore, three domains at positions 283–308,
55–386, and 461–480 aa also contain the most immu-
oreactive epitopes, as modeled with synthetic peptides.
hree peptides derived from regions at positions 362–
86 and 461–480 aa demonstrated high background im-
unoreactivity (Table 1). Peptide 1261 demonstrated
onspecific immunoreactivity with 1 of 46 anti-HAV-neg-
tive specimens under the experimental conditions that
ere uniformly applied to all synthetic peptides (see
aterials and Methods).
Peptides derived from regions at positions 290–302 aa
Kulik et al., 1994), 321–330 aa (Chikin et al., 1991), 355–
66 aa (Bosch et al., 1998), and 382–395 aa (Kulik et al.,
994, 1995) were previously tested for antigenic reactivity
ith human anti-HAV-positive convalescent-phase se-
um specimens and with monoclonal antibodies. Except
or peptide containing the sequence 321–330 aa, three of
hese peptides were found to be immunoreactive. It is
nteresting that the sequence of the nonimmunoreactive
eptide was represented within two immunoreactive
verlapping peptides, 1243 (314–333 aa) and 1244 (321–
40 aa), described in the present study (Table 1). Con-
ersely, the peptide containing the sequence 382–395 aa
as been previously reported as immunoreactive (Kulik
t al., 1994, 1995); however, peptide 1251 (380–399 aa),
hich contains this complete sequence, was not found
o be immunoreactive in our study (Table 1). Peptide 1250
367–386 aa) and 1252 (391–410 aa) are partially over-
apped with an antigenic epitope at position 382–395 aa
reviously identified by Kulik et al. (1995). However, these
eptides do not appear to model this epitope because
either peptide contains the complete sequence of this
pitope. The antigenic reactivity of two other peptides
ontaining sequences at positions 290–302 aa (Kulik et
l., 1994) and 355–366 aa (Bosch et al., 1998) was con-
irmed in the present study with peptides 1235 (283–302
a) and 1248 (355–374 aa) (Table 1). 1Three weakly immunoreactive peptides (1241, 1242,
nd 1243) contain residues Asp315 and Gln319, which have
een found to be essential residues of the HAV major
onformational neutralizing epitope (Lemon, 1992; Ping
t al., 1988; Ping and Lemon, 1992). These peptides also
ontain the region at position 308–321 aa, known to elicit
ntibody that recognizes HAV particles (Lemon, 1992).
VP1 protein. Among 52 synthetic peptides spanning
he entire HAV VP1 protein, 15 were found to be anti-HAV
mmunoreactive (Fig. 1). These peptides identify nine
ntigenic domains (Table 1). Six domains at positions
27–546, 572–591, 584–603, 651–670, 734–753, and 754–
73 aa were identified with only one peptide each. The
-terminal domain at position 501–526 aa was identified
ith 2 peptides, while the C-terminal domain at position
67–798 aa was identified with 3 peptides. One domain
t position 543–578 aa was identified with 4 peptides
Table 1). Five peptides (1266, 1273, 1276, 1313, and 1314)
erived from four antigenic domains were found to be
mmunoreactive with more than 30.0% of anti-HAV-posi-
ive serum specimens. However, 2 of these broadly im-
unoreactive peptides demonstrated a two times higher
ackground reactivity with anti-HAV-negative specimens
ompared to all the other peptides (Table 1). Moreover, 1
f these 2 peptides, 1273, was shown to immunoreact
ith 3 of 48 anti-HAV-negative specimens, thus demon-
trating nonspecific reactivity. Another broadly immuno-
eactive peptide, 1313, also demonstrated nonspecific
eactivity with about 6.0% of anti-HAV-negative serum
pecimens (Table 1). It should be noted that 10 of 15
P1-derived immunoreactive peptides were shown to
xhibit HAV nonspecific antigenic reactivity compared to
nly 2 peptides among all peptides derived from both
P2 and VP3 proteins (Table 1). It should be emphasized,
owever, that the assay experimental conditions were
niformly applied to all synthetic peptides without regard
o optimizing assay conditions for each peptide (see
aterials and Methods). It is likely that with proper
ptimization, especially for the concentration of each
eptide adsorbed to microtiter wells, the nonspecific
mmunoreactivity might be significantly reduced or elim-
nated.
A number of peptides derived from the HAV VP1 pro-
ein were previously tested for antigenic reactivity. Pep-
ide containing the sequence at position 502–516 aa was
hown to elicit HAV neutralizing antibodies (Bosch et al.,
998; Emini et al., 1985; Lemon et al., 1992). This peptide
as also recently found to be immunoreactive with anti-
AV antibodies (Bosch et al., 1998). This finding contra-
icts a previous study in which no antigenic reactivity
as found associated with a peptide of the same se-
uence (Kulik et al., 1994, 1995). In our experiments, the
eptide 1265, completely comprising the sequence of
his peptide, was shown to immunoreact with 22.0% of
cute-phase anti-HAV-positive serum specimens (Table
), thereby confirming the presence of an antigenically
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266 KHUDYAKOV ET AL.eactive epitope within this region of the HAV VP1 pro-
ein.
Another antigenic region within the HAV VP1 protein
as previously found by using a set of three peptides
ontaining the sequence 606–630 aa (Kulik et al., 1994,
995). However, this observation was not confirmed by
esults obtained with peptide 609–631 aa (Chikin et al.,
991), which was found not to be immunoreactive. In our
tudy, we also could not confirm the presence of an
ntigenic epitope(s) within this region, since peptide
284 containing the sequence 606–625 aa did not show
ny HAV-specific antigenic reactivity.
Additionally, a set of peptides derived from regions at
osition 492–508, 564–577, 589–599, 599–614, and 767–
89 aa was previously tested with anti-HAV-positive se-
um specimens (Chikin et al., 1991). None of these pep-
ides, however, was found to be immunoreactive. In this
tudy, two peptides, 1264 (490–509 aa) and 1283 (598–
17 aa), comprising two of these regions, were also
onimmunoreactive, thus confirming the absence of an-
igenic reactivity within regions 492–508 and 599–614 aa.
owever, peptide 1274 (559–578 aa), 1279 (584–603 aa),
312 (767–786 aa), and 1313 (772–791 aa), which com-
letely comprised sequences from the other three re-
ions, were found to be immunoreactive, with peptide
313 demonstrating the strongest and broadest immu-
oreactivity (Table 1). Interestingly, immunoreactive pep-
ide 1279 contains Ser102, which was shown to be an
mportant residue of the major HAV neutralizing antigenic
pitope (Lemon, 1992; Ping et al., 1988; Ping and Lemon,
992). Immunoreactive peptide 1290 (Table 1) contains
nother two amino acids, Val171 and Ala176, also shown to
e essential for the activity of this neutralizing epitope
Lemon, 1992; Ping et al., 1988; Ping and Lemon, 1992).
Peptides 1304, 1305, 1306, and 1307 are located within
he region at position 714–752 aa that was previously
hown to be exposed on the surface of HAV particles
Robertson et al., 1989). Surface exposure is generally
onsidered to be an important indicator of potential an-
igenic reactivity (Emini et al., 1985); however, among
hese peptides, only peptide 1307 was found to be im-
unoreactive (Table 1).
mmunoreactivity of peptides derived from
onstructural proteins
The antigenic composition of the entire HAV nonstruc-
ural area has not been previously reported. It is known,
owever, that the nonstructural proteins are antigenically
eactive and may bind antibodies from anti-HAV-positive
erum specimens (Jia et al., 1992; Robertson et al., 1992,
993; Steward et al., 1997). Nevertheless, no attempt has
een made to map antigenic epitopes within these pro-
eins.
P2A protein. Five peptides, 1315, 1316, 1317, 1318, and319, were synthesized to span the entire P2A protein fFig. 1). Among these peptides, four were found to be
mmunoreactive (Table 2). All antigenically active P2A
eptides could bind antibodies from 31.3 to 83.3% of
cute-phase anti-HAV-positive serum specimens with av-
rage P/N values varying from 5.94 to 19.35 (Table 2).
eptide 1317 immunoreacted with 83.3% of acute-phase
erum specimens and as such represents the most im-
unoreactive peptide found in the present study. Thus,
he HAV nonstructural P2A protein is very antigenically
eactive (Fig. 1). However, the P2A antigenic domain
hould be considered an extension to the C-terminal
ntigenic domain of the HAV VP1 protein since all over-
apping consecutive peptides from 1312 to 1318 were
trongly immunoreactive (Tables 1 and 2). Thus, the re-
ion spanned by these peptides at position 767–842 aa
hat comprise the C-terminal sequence of the VP1 pro-
ein and almost the entire P2A protein may be consid-
red as one immunodominant domain of the HAV
olyprotein (Fig. 1B, region 2).
P2B protein. Among 18 peptides derived from the HAV
2B protein, only 2 were found to be immunoreactive
Figs. 1D and 1E). These immunoreactive peptides iden-
ified two small independent antigenic domains at posi-
ions 922–941 and 961–980 aa (Table 2). Both peptides
ere very immunoreactive as evidenced by each peptide
eacting with approximately 30.0% of acute-phase HAV
erum specimens. The HAV P2B protein is the least
mmunoreactive region compared to all other HAV pro-
eins, as assessed by the antigenic reactivity of synthetic
eptides.
P2C protein. Among 30 peptides spanning this protein,
0 were found to be immunoreactive (Figs. 1D and 1E).
hese immunoreactive peptides identified six antigenic
omains (Table 2). The N-terminal and the C-terminal
omains at positions 1133–1152 and 1403–1422 aa, re-
pectively, were identified with only one peptide each.
wo internal domains at positions 1261–1280 and 1299–
318 aa were also identified with one peptide each. One
omain at position 1210–1239 aa was identified with two
eptides, while the domain at position 1331–1379 aa was
panned by four immunoreactive peptides (Table 2).
one of the HAV P2C peptides was immunoreactive with
ore than 30.0% serum specimens. The most immuno-
eactive peptides, 1347, 1348, and 1367, were found to be
mmunoreactive with only 22.0–29.2% of sera (Table 2).
P3A protein. This protein contains only one antigenic
omain (Table 2), located at the N-terminal region (Fig.
B). Among six peptides spanning this protein, three
ere found to be immunoreactive; two of these peptides,
368 and 1369, demonstrated strong immunoreactivity
Table 2). Consistent with the definition of an antigenic
omain as presented in this paper, the P3A antigenic
omain should be extended to include the C-terminus of
he P2C protein, where immunoreactive peptide 1367
rom the P2C protein is consecutive with peptide 1368
rom the P3A protein (Table 2). Thus, as observed for the
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267ANTIGENIC EPITOPES OF HEPATITIS A VIRUS2A protein, the P3A protein contains one very strong
ntigenic domain that extends into the C-terminus of the
receding protein.
P3B protein. This short 23-aa protein was spanned by
nly one peptide, 1374 (Fig. 1), which demonstrated very
road and strong antigenic reactivity (Table 2). This pep-
ide and those derived from P2A and P3A proteins rep-
esent the most diagnostically relevant peptides identi-
T
Antigenic Reactivity of Synthetic Peptides
Note. Alternating boldface and italic type represent individual an
1 The number of positive serum samples divided by the total num
2 Mean P/N value; number in parentheses indicates the range o
3 Normal human sera.ied in this study. tP3C protein. Among 19 peptides synthesized span-
ing the entire P3C protein, 6 were immunoreactive
Figs. 1D and 1E). One peptide, 1393, derived from the
ery C-terminus was found to be one of the most
mmunoreactive peptides described in this study (Ta-
le 2) as evidenced by its reacting with almost 60.0%
f acute-phase anti-HAV-positive serum specimens.
he HAV P3C protein contains four antigenic domains,
ed from the HAV Nonstructural Proteins
domains.
tested sera and percentage of immunoreactive sera.
alues.ABLE 2
Deriv
tigenic
ber of
f P/N vhree of which were identified with one peptide each.
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268 KHUDYAKOV ET AL.ne domain was identified with three peptides (Ta-
le 2).
P3D protein. Forty-eight peptides were derived from
his protein; 13 were found to be immunoreactive (Fig. 1).
hese immunoreactive peptides identified eight anti-
enic domains (Table 2). Four domains were identified
ith one peptide each, three were identified with 2 pep-
ides each, and one was identified with 3 peptides (Table
). Peptide 1394 was the most immunoreactive among all
he P3D peptides. This peptide immunoreacted with ap-
roximately 32.0% of anti-HAV-positive acute serum
pecimens (Table 2). Similar to the P2A and P3A pro-
eins, the P3D N-terminal antigenic domain may be ex-
ended into the C-terminal region of the P3C protein
Table 2).
mmunoreactivity of peptides with HAV
eroconversion panels
All synthetic peptides presented in Tables 1 and 2 were
ested with seven anti-HAV seroconversion panels ob-
ained from HAV-infected patients (n 5 2) and from exper-
mentally infected chimpanzees (n 5 5; see Materials and
FIG. 2. IgG and IgM anti-HAV immunoreactivity of synthetic peptides
himpanzee 1357. Shaded area shows the ALT level. HAVAB/HAVAB-M
AVAB-M and HAVAB diagnostic tests, respectively; plus and minus sig
ot tested.ethods). A specific seroconversion pattern of antibodyinding was detected for all peptides. This finding demon-
trates that the peptides shown in Table 1 and 2 specifically
etected anti-HAV antibodies. The majority of the peptides
emonstrated both IgG and IgM anti-HAV activity. A few
xamples of specific reactivity for representative peptides
rom each HAV protein, with follow-up serum specimens
btained from experimentally infected chimpanzee 1357
nd with seroconversion panel RP-004 obtained from an
AV-infected patient, are shown in Figs. 2 and 3, respec-
ively. It is interesting to note that IgM antibody can be
etected with synthetic peptides for approximately the
ame period of time as with cell culture-derived antigen
sed in the commercially available test (HAVAB-M, Abbott
aboratories), whereas IgG anti-HAV activity can be de-
ected for a much shorter period compared to HAVAB (Figs.
and 3). This observation may be explained by a relatively
ower immunoreactivity with convalescent-phase anti-HAV-
ositive serum samples of even strongly immunoreactive
eptides such as peptide 1317 (data not shown) in concor-
ance with previous observations using synthetic peptides
nd convalescent-phase serum specimens (Bosch et al.,
998; Chikin et al., 1991; Kulik et al., 1994, 1995).
seroconversion panel obtained from an experimentally HAV-infected
shows the results for the detection of IgM and total antibodies with
ate positive and negative results of testing; the other specimens werewith a
panel
ns indicAlmost all synthetic peptides demonstrated a uni-
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269ANTIGENIC EPITOPES OF HEPATITIS A VIRUSorm pattern of immunoreactivity with the various se-
oconversion panels, as can be seen in Figs. 2 and 3A.
ome peptides, however, showed a slightly different
attern of immunoreactivity (Fig. 3B). For example,
eptides 1250 and 1315 (Fig. 3B) showed a typical
eactivity with the seroconversion panel RP-004, which
s very similar to the patterns seen with other peptides
n Figs. 2 and 3A; by contrast, peptides 1243 and 1327
howed a “delayed” immunoreactivity pattern. It is in-
eresting to note that peptides 1241, 1243, and 1250,
hich all belong to the VP3 protein, demonstrated two
istinct patterns of immunoreactivity, typical and de-
ayed (Fig. 3B).
ntigenic composition of the HAV polyprotein
In the present study a number of antigenic epitopes
ere identified by using synthetic peptides (Tables 1 and
). These antigenic epitopes were modeled with 75 pep-
FIG. 3. IgG and IgM anti-HAV immunoreactivity of synthetic peptides
or the detection of IgM and total antibodies with HAVAB-M and HAVAides almost uniformly scattered across the entire HAV polyprotein (Fig. 1). As mentioned above, some antigenic
pitopes from the structural proteins had been previ-
usly discovered (Bosch et al., 1998; Emini et al., 1985;
ulik et al., 1994, 1995), whereas none of the nonstruc-
ural antigenic epitopes had been previously identified.
he finding of strong antigenic epitopes within the non-
tructural proteins corroborates previous observations
hat antibodies specific to nonstructural proteins may be
etected in anti-HAV-positive serum samples with pro-
ein products expressed in an in vitro transcription–trans-
ation system (Jia et al., 1992; Robertson et al., 1992, 1993;
tewart et al., 1997).
By the use of synthetic peptides, 40 antigenic domains
ere found scattered along the entire polyprotein, and
ntigenic epitopes were identified within every HAV pro-
ein. An assessment of the antigenic reactivity of pep-
ides reveals that, in general, structural proteins showed
n average antigenic reactivity, whereas nonstructural
e seroconversion panel RP-004. HAVAB/HAVAB-M panel shows results
ostic tests, respectively.with throteins such as P2A, P3A, and P3B are very antigeni-
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270 KHUDYAKOV ET AL.ally reactive (Figs. 1D, 1E, and 1F). Protein P2B, how-
ver, is the least immunoreactive (Fig. 1B). Approximately
0 of 75 immunoreactive peptides demonstrated a per-
entage immunoreactivity (Fig. 1D) and an average P/N
alue (Fig. 1E) greater than the average value calculated
or all immunoreactive peptides. Only 13 peptides (1211
rom VP2, 1266, 1312, 1313, and 1314 from VP1, 1315, 1316,
nd 1317 from P2A, 1368, 1369, and 1370 from P3A, 1374
rom P3B, and 1393 from P3C) were found to exceed the
verage level for both parameters (Figs. 1D and 1E).
mong these 13 peptides, only 9 (1211, 1313, 1314, 1315,
317, 1368, 1369, 1374, and 1393) were identified with an
ntigenic index (see Materials and Methods) that was
wo times greater than the average value for the entire
olyprotein (Fig. 1F). These 9 peptides belong to five
ntigenic domains (Fig. 1B). Domain 1, which is the only
tructural domain among the five strong antigenic do-
ains, is located at position 57–90 aa. Domain 2, at
osition 767–842 aa, encompasses the C-terminal region
f the VP1 protein and the entire P2A protein. Domain 3
ontains the C-terminal region of the P2C protein and the
-terminal region of the P3A protein at position 1403–
456 aa. Domain 4 contains almost the entire P3B protein
t position 1500–1519 aa. Domain 5 contains the
-terminal region of the P3C protein and the N-terminal
egion of the P3D protein at position 1719–1764 aa (Fig.
B, Tables 1 and 2). It is interesting to note that three of
he five strong antigenic domains such as domains 2, 3,
nd 5 contain the predicted protease cleavage sites (Fig.
B). Another interesting observation is that domains 2, 3,
nd 4 belong to the smallest HAV proteins, P2A, P3A, and
3B. All five strong antigenic domains are hydrophilic
Fig. 1H) and are folded into alpha-helices separated by
trong beta-turns (Fig. 1G), as predicted using computer-
ssisted analysis of secondary structure (Chou, 1990).
omain 2, the most immunoreactive domain, comprises
he most hydrophilic region, which is also part of the
argest predicted alpha-helical region within the HAV
olyprotein (Figs. 1G and 1H).
An analysis of the immunoreactivity of synthetic pep-
ides with HAV seroconversion panels demonstrated that
oth IgM and IgG antibodies can be detected with syn-
hetic peptides for a short period of time around the
cute phase of HAV infections (Figs. 2 and 3). A similar
attern of reactivity was found for peptides derived from
oth structural and nonstructural proteins. This finding
uggests that several HAV-specific antigenic epitopes,
hich can be efficiently modeled with synthetic peptides,
licit antibodies for only a short time. Alternatively, syn-
hetic peptides, because of some innate property such
s low avidity of antibody binding, can efficiently detect
nti-HAV antibodies only during the acute phase of in-
ection. Recently, a similar short-term antibody response
as observed with a recombinant P3C protein (Stewart
t al., 1997). This observation, taken together with ourindings, strongly suggests that the immune response to 1he HAV nonstructural proteins is usually of short dura-
ion. Nevertheless, synthetic peptides or antigenic
pitopes identified in the present study may have poten-
ial diagnostic application, especially for the detection of
cute HAV infections currently diagnosed by the detec-
ion of IgM anti-HAV using cell-culture-derived virus as
he antigenic target. Recombinant proteins or synthetic
eptides from the structural proteins have not been suc-
essfully used as alternative sources of antigen in the
evelopment of enzyme immunoassays for the detection
f anti-HAV because of apparently poor antigenic reac-
ivity. Poor performance of these antigens has been ex-
lained by the strictly conformational nature of HAV an-
igenic epitopes (Lemon, 1992). In addition, current com-
ercially available assays are unable to discriminate
etween natural infections and vaccine-induced immu-
ity (Jia et al., 1992; Robertson et al., 1992, 1993; Stewart
t al., 1997). Antigenic domains discovered within the
AV nonstructural proteins may be most suitable for
eveloping such an assay. Finally, data derived in the
resent study may be used to construct recombinant
roteins or artificial antigens similar to the mosaic hep-
titis E antigen (Khudyakov et al., 1994) and used as
ntigenic targets in the development of diagnostic tests
or the detection of acute HAV infections.
MATERIALS AND METHODS
ynthetic peptides
Peptides were synthesized by FMOC chemistry
Barany and Merrifield, 1980) on an ACT Model MPS 350
ultiple peptide synthesizer (Advanced Chemtech, Lou-
sville, KY) according to the manufacturer’s protocols.
fter characterization by amino acid analysis, high-per-
ormance liquid chromatography, and capillary electro-
horesis, peptides were characterized by enzyme immu-
oassay.
erum samples
All anti-HAV-positive serum samples collected from
nti-HAV-positive patients with acute liver disease and
nti-HAV-negative serum samples collected from normal
lood donors were randomly selected from a collection
eposited at the Centers for Disease Control and Preven-
ion (Atlanta, GA). All serum specimens were initially
ested by commercially available kits for the presence of
gG and IgM anti-HAV activity (HAVAB and HAVAB-M,
bbott Laboratories, North Chicago, IL).
nzyme immunoassay for anti-HAV
Synthetic peptides (110 ml) at a concentration of 10
g/ml in 0.1 M phosphate-buffered saline (PBS), pH 7.5,
ere adsorbed to microtiter wells (Immulon II, Dynatech
ndustries, Inc., McLean, VA) at room temperature for
2 h. Serum specimens were diluted in PBS containing
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271ANTIGENIC EPITOPES OF HEPATITIS A VIRUS.1% Tween 20 and 10% normal goat serum (PBS-T); 100
l of diluted specimens was added to each well, incu-
ated for 60 min at 37°C, and washed with PBS contain-
ng Tween 20. Two different dilutions of specimen and
etector antibodies were used. One set of serum spec-
mens was diluted 1:100. The antibody binding was de-
ected by adding 100 ml of affinity-purified anti-human
gG coupled to horseradish peroxidase (HRP) (Boehr-
nger Mannheim Biochemicals, Indianapolis, IN) diluted
:30,000 and by incubating it for 1 h at 37°C. The second
et of serum specimens was diluted 1:1000. In this case,
0 ml of affinity-purified anti-human IgG conjugated to
iotin diluted 1:8000 and 50 ml of streptavidin coupled to
RP were added to microtiter wells and incubated for 30
in at 37°C. Two different cut-offs were established to
dentify anti-HAV specific immunoreactivity. The first cut-
ff, expressed as a P/N ratio and equal to 3.0, was
tatistically established as the mean of negative controls
lus at least 3.5 standard deviations (SD) above the
ean, where P represents the optical density value at
93 nm (OD493) of anti-HAV-positive specimens and N
epresents the OD value of negative controls. An addi-
ional cut-off was used to ensure statistical reliability and
ccurate interpretation of positive results. In this case, in
ddition to anti-HAV-negative serum, two irrelevant syn-
hetic peptides were used as supplemental negative
ontrols to determine the degree of nonspecific binding
f anti-HAV serum to synthetic peptides. One cut-off,
xpressed as a P/N ratio and equal to 3.0, corresponded
o the mean of negative serum controls plus at least 3.5
D above the mean. A second cut-off was also ex-
ressed as a P/N ratio, where P represents the OD value
t 493 nm (OD493) for HAV peptides immunoreacting with
nti-HAV-positive specimens and N represents the OD
alue obtained with the irrelevant peptides. The second
ut-off was equal to 2.0. Synthetic peptides were consid-
red immunoreactive with anti-HAV serum specimens
nly when both criteria were satisfied. Tables 1 and 2
nd Fig. 1 show P/N values obtained by using the anti-
AV-negative serum specimens.
The antigenic index, designated the A index (Fig. 1F),
as derived by multiplying the mean of P/N values and
ercentage of serum specimens immunoreactive with
ach synthetic peptide (Tables 1 and 2) and therefore
epresents a measure of both the strength and the
readth of the immunoreactivity of each peptide with
erum specimens. When antigenic properties of different
eptides are compared, the A index can be calculated as
he mean of P/N values for all anti-HAV-positive serum
pecimens tested with each peptide. Thus, the A index
ombines such parameters as the mean of P/N values of
pecimens tested positive with each peptide and the
ercentage of serum specimens immunoreactive with
ach peptide. In this study, because the mean of P/N
alues for specimens immunoreactive with each peptide
nd the percentage of immunoreactive sera were calcu- pated long before, the A index was calculated as de-
cribed above. This calculation gives different absolute
alue without affecting the relative value of the A index
alculated as the mean of P/N in rating antigenic quality
f synthetic peptides. We found that the A index in com-
ination with such parameters as the average P/N of
ositive specimens and the percentage of immunoreac-
ive serum specimens (Figs. 1D, 1E, and 1F) is a very
elpful indicator of antigenic potential of peptides and as
uch was used in this study to measure the diagnostic
elevance of each individual peptide.
AV seroconversion panels
Two anti-HAV seroconversion panels, RP-004 and RP-
13 (Profile Diagnostics, Inc., Sherman Oaks, CA), were
sed in this study. Panel RP-004 contains 15 members
ollected over 63 days from a patient with symptoms of
epatitis A infection including jaundice, malaise, dehy-
ration, and elevated levels of alanine aminotransferase
ALT). Panel RP-013 also contains 15 members collected
ver 189 days from a patient with symptoms of hepatitis
infection.
Five seroconversion panels were obtained from exper-
mentally HAV-infected chimpanzees (chimps 1357, 1402,
439, 1487, and 1489). Chimp 1357 was injected intrave-
ously with 106 chimpanzee infectious doses of wild-type
LD-2 HAV inoculum. Chimp 1402 was inoculated intra-
enously with 25 ng of live, attenuated virus (HAS-15,
60S fraction after sucrose gradient purification) without
djuvant, which resulted in no ALT elevation and no
eroconversion. This animal was challenged with 1 ml
ild-type virus (HLD-2) inoculated intravenously 218 days
fter the first inoculation. Chimps 1487 and 1489 were
noculated via an oral gastric tube with 1 ml SD-11
uman stool suspension in veal broth (kindly provided by
r. R. H. Purcell) containing 100 chimpanzee oral infec-
ious doses. Chimp 1439 was inoculated intragastrically
ith a 10% stool suspension obtained from an experi-
entally HAV-infected cynomogus macaque (145), which
esulted in no anti-HAV seroconversion and no ALT ele-
ation, and was subsequently challenged with 1 ml wild-
ype virus (HLD-2) inoculated intravenously 145 days
fter the first inoculation. All animals exhibited ALT ele-
ations and seroconverted following inoculation with
AV HLD-2. Twelve follow-up serum specimens col-
ected from each animal over ;100 days after the inoc-
lation were used to test the immunoreactivity of syn-
hetic peptides in the present study.
omputer-assisted analysis
Amino acid sequence analysis was performed by us-
ng the Protean program from the Lasergene software
ackage (DNASTAR Inc., Madison, WI). Hydropathic
lots were built by the Kyte and Doolittle (1982) method
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272 KHUDYAKOV ET AL.nd protein secondary structure was predicted by the
hou and Fasman method (see Chou, 1990).
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